Short Bowel Patients Treated for Two Years with Glucagon-Like Peptide 2 (GLP-2): Compliance, Safety, and Effects on Quality of Life

Table 4

Inflammatory Bowel Disease Questionnaire, IBDQ (7∼Best).

(mean±SD, 𝑛=8)	1st year				2nd year
	Baseline	Week 13	Week 26	Week 52	Washout	Week 13	Week 26	Week 52	P-value
Treatment	None	GLP-2	GLP-2	GLP-2	None	GLP-2	GLP-2 + Cholyl-sarcosine	GLP-2
Overall	5.1±0.9	5.3±0.9	5.3±1.0	5.4±0.9	4.9±1.0	5.4±0.8	5.5±0.8	5.4±0.9	0.007
Bowel Symptoms	5.3±0.6	5.5±0.8	5.3±0.8	5.5±0.7	5.2±0.8	5.5±0.6	5.5±0.8	5.4±0.7	0.61
Systemic Symptoms	4.0±1.4	4.5±1.6	4.9±1.4	4.7±1.2	3.7±1.6	4.2±1.4	4.4±1.3	4.9±1.4	0.03
Emotional Function	5.5±1.1	5.7±1.1	5.6±1.2	5.7±1.1	5.5±1.1	5.7±0.8	5.9±0.8	5.7±1.0	0.44
Social Function	5.0±1.3	5.0±1.5	5.2±1.4	5.1±1.4	4.5±1.4	5.3±1.5	5.4±1.1	5.3±1.4	0.03

* ∼𝑃<.05, compared to baseline by Dunnett’s test.